The DOI matches its Crossref record; 192 of the 195 references it cites were found in a registry or an index.
AAV Capsid Structure and Cell Interactions
Abstract
The Adeno-associated viruses (AAVs) are not associated with any diseases, and their ability to package non-genomic DNA and to transduce different cell/tissue populations has generated significant interest in understanding their basic biology in efforts to improve their utilization for corrective gene delivery. This includes their capsid structure, cellular tropism and interactions for entry, uncoating, replication, DNA packaging, capsid assembly, and antibody neutralization. The human and nonhuman primate AAVs are clustered into serologically distinct genetic clade and serotype groups, which have distinct cellular/tissue tropisms and transduction efficiencies. These properties are highly dependent upon the AAV capsid amino acid sequence, their capsid structure, and their interactions with host cell factors, including cell surface receptors, co-receptors, signaling molecules, proteins involved in host DNA replication, and host-derived antibodies. This chapter reviews the current structural information on AAV capsids and the capsid viral protein regions playing a role in the cellular interactions conferring an infective phenotype, which are then used to annotate the functional regions of the capsid. Based on the current data, the indication is that the AAVs, like other members of the Parvoviridae and other ssDNA viruses that form a T = 1 capsid, have evolved a multifunctional capsid with conserved core regions as is required for efficient capsid trafficking, capsid assembly, and genome packaging. Disparate surface loop structures confer differential receptor recognition and are involved in antibody recognition. The role of structural regions in capsid uncoating remains to be elucidated.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The unique topology of the AAV capsid confers cellular tropism by differential receptor binding.”
From Characterization of a novel adeno-associated viral vector with preferential oligodendrocyte tropism (2016) · cites this paper as [18]
In the citing paper
“The first step of AAV transduction entails AAV binding to a primary receptor and co-receptor on the cell surface.18”
From Characterization of a novel adeno-associated viral vector with preferential oligodendrocyte tropism (2016) · cites this paper as [18]
In the citing paper
“The AAV capsids have nine variable regions surrounded by conserved regions where the variable regions form loops and clusters on the exterior of the capsid.18–19”
From Characterization of a novel adeno-associated viral vector with preferential oligodendrocyte tropism (2016) · cites this paper as [18]
In the citing paper
“These protrusions are formed from interdigitating loops from two VPs and have the most extensive VP–VP interactions [23,24].”
From Understanding Capsid Assembly and Genome Packaging for Adeno-Associated Viruses (2017) · cites this paper as [24]
In the citing paper
“This region has the least number of VP–VP interface interactions and represents the thinnest region of the virus capsid shell [23,24].”
From Understanding Capsid Assembly and Genome Packaging for Adeno-Associated Viruses (2017) · cites this paper as [24]
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163
Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520
Summerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,409
Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues
Gao, G., Vandenberghe, L. H., Alvira, M. R., Lu, Y., Calcedo, R., Zhou, X., & Wilson, J. M. (2004) · Journal of Virology · doi:10.1128/jvi.78.12.6381-6388.2004 · Cited by 1,070
Effect of genome size on AAV vector packaging
Wu, Z., Yang, H., & Colosi, P. (2010) · Molecular Therapy · doi:10.1038/mt.2009.255 · Cited by 1,029
Real-Time Single-Molecule Imaging of the Infection Pathway of an Adeno-Associated Virus
Seisenberger, G., Ried, M. U., Endreß, T., Büning, H., Hallek, M. J., & Bräuchle, C. (2001) · Science · doi:10.1126/science.1064103 · Cited by 819
Rabinowitz, J. E., Rolling, F., Li, C., Conrath, H., Xiao, W., Xiao, X., & Samulski, R. J. (2002) · Journal of Virology · doi:10.1128/jvi.76.2.791-801.2002 · Cited by 762
Ferrari, F. K., Samulski, T., Shenk, T., & Samulski, R. J. (1996) · Journal of Virology · doi:10.1128/jvi.70.5.3227-3234.1996 · Cited by 761
αVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection
Summerford, C., Bartlett, J. S., & Samulski, R. J. (1999) · Nature Medicine · doi:10.1038/4768 · Cited by 711
The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy
Xie, Q., Bu, W., Bhatia, S., Hare, J., Somasundaram, T., Azzi, A., & Chapman, M. S. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.162250899 · Cited by 612
Research works printed but not linked: 6
- Chapman, M. S., and Agbandje-McKenna, M. (2006) Atomic structure if viral particles., in Parvoviruses (Kerr, J. R., Cotmore, S. F., Bloom, M. E., Linden, R. M., and Parrish, C. R., Eds.), pp 107–123, Edward Aenold Ltd. New York, New York.
- Akache, B., Grimm, D., Pandey, K., Yant, S. R., Xu, H., and Kay, M. A. (2006) The 37/67-kilodalton laminin receptor is a receptor for adeno-associated virus serotypes 8, 2, 3, and 9, J Virol 80, 9831–9836. · DOI
- Hansen, J., Qing, K., and Srivastava, A. (2001) Adeno-associated virus type 2-mediated gene transfer: altered endocytic processing enhances transduction efficiency in murine fibroblasts, J Virol 75, 4080–4090. · DOI · Paper page
- Xiao, W., Warrington, K. H., Jr., Hearing, P., Hughes, J., and Muzyczka, N. (2002) Adenovirus-facilitated nuclear translocation of adeno-associated virus type 2, J Virol 76, 11505–11517. · DOI
- Knipe, D. M., and Howley, P. M. H. (2001) Fields Viroloy, Lippincott Williams&Wilkins, Philadelphia, USA.
- Sonntag et al (2010) PNAS 107, 10220–10225. · DOI · Paper page
Cited by
Sorted by citations
Items 101–200 of 217
Diversity and Evolution of Novel Invertebrate DNA Viruses Revealed by Meta-Transcriptomics
Porter, A. F., Shī, M., Eden, J., Zhang, Y., & Holmes, E. C. (2019) · Viruses · doi:10.3390/v11121092 · Cited by 22
“To overcome this, some parvoviruses co-infect with helper viruses [58,61], while others are adapted to infect cell types that undergo S phase in their cell cycle.”
BackgroundZoratto, S., Weiss, V. U., Friedbacher, G., Buengener, C., Pletzenauer, R., Foettinger‐Vacha, A., Graninger, M., & Allmaier, G. (2021) · ACS Omega · doi:10.1021/acsomega.1c01443 · Cited by 22
Tse, L. V., Møller-Tank, S., Meganck, R. M., & Asokan, A. (2018) · Journal of Virology · doi:10.1128/jvi.00393-18 · Cited by 23
Schwinghamer, K., & Siahaan, T. J. (2023) · Journal of Nanotheranostics · doi:10.3390/jnt4040020 · Cited by 21
Abulimiti, A., Lai, M. S., & Chang, R. C. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111549 · Cited by 23
Chemical approaches to probe and engineer AAV vectors
Pham, Q. T., Glicksman, J., & Chatterjee, A. (2024) · Nanoscale · doi:10.1039/d4nr01300j · Cited by 24
“14 15 – 17 This secondary interaction initiates diverse internalization pathways, resulting in tra ffi cking to endosomal and Golgi compartments.”
BackgroundMolecular Engineering of Virus Tropism
He, B., Wilson, B., Chen, S., Sharma, K., Scappini, E., Cook, M., Petrovich, R. M., & Martin, N. P. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252011094 · Cited by 22
Mietzsch, M., Hull, J. A., Makal, V., Ybargollin, A. J., Yu, J. C., McKissock, K., Bennett, A. D., Pénzes, J. J., Lins, B., Yu, Q., et al. (2022) · Journal of Virology · doi:10.1128/jvi.00335-22 · Cited by 19
“associated with glycan and protein receptor attachment (31, 32, 37), transduction (38–40), and”
BackgroundSelf-citationZheng, N., Li, M., Wu, Y., Kaewborisuth, C., Li, Z., Gui, Z., Wu, J., Cai, A., Lin, K., Su, K., et al. (2022) · NeuroImage · doi:10.1016/j.neuroimage.2022.119402 · Cited by 19
Muzyczka, N., & Berns, K. I. (2015) · Molecular Therapy · doi:10.1038/mt.2015.55 · Cited by 21
Daniel, H. D. J., Kumar, S., Kannangai, R., Lakshmi, K. M., Agbandje‐McKenna, M., Coleman, K. E., Srivastava, A., Srivastava, A., & Abraham, A. M. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.258 · Cited by 19
“4 Their lack of pathogenicity, the persistent expression of the transgene, and the availability of many serotypes have made AAV an important gene therapy vector.”
Self-citationLiu, S., Chowdhury, E. A., Xu, V., Jerez, A., Mahmood, L., Ly, B. Q., Le, H. K., Nguyen, A., Rajwade, A., Meno‐Tetang, G. M. L., et al. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.10.005 · Cited by 18
Cellular and Natural Viral Engineering in Cognition-Based Evolution
Miller, W. B., Reber, A. S., Marshall, P., & Baluška, F. (2023) · Communicative & Integrative Biology · doi:10.1080/19420889.2023.2196145 · Cited by 18
“viral assembly, and genome packaging [167].”
Characterization of Naturally-Occurring Humoral Immunity to AAV in Sheep
Tellez, J., Van Vliet, K., Tseng, Y.-S., Finn, J. D., Tschernia, N., Almeida-Porada, G., Arruda, V. R., Agbandje-McKenna, M., & Porada, C. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0075142 · Cited by 18
“permitting some degree of tissue-targeting [4-7].”
Self-citationAdvances in viral vector-based delivery systems for gene therapy: a comprehensive review
Singh, K., Jain, D., Sethi, P., Gupta, J. K., Dubey, A., Noman, A. A., lal, S., Sharma, P., & Abdallah, E. M. (2025) · 3 Biotech · doi:10.1007/s13205-025-04366-7 · Cited by 21
“…may typically be compacted to a maximum size of less than 4.7 kb. AAV vectors can transduce specific cells or tissues via the encapsulation of non-genomic DNA that is unrelated to any neurodegenerative or CNS disorder (Pillay et al. 2016; Agbandje-McKenna and Kleinschmidt 2011; Gray et al. 2010).”
InfluentialKelemen, R. E., Erickson, S. B., & Chatterjee, A. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-7574-7_20 · Cited by 17
Structural Study of Aavrh.10 Receptor and Antibody Interactions
Mietzsch, M., Yu, J. C., Hsi, J., Chipman, P. R., Broecker, F., Fuming, Z., Linhardt, R. J., Seeberger, P. H., Heilbronn, R., McKenna, R., et al. (2021) · Journal of Virology · doi:10.1128/jvi.01249-21 · Cited by 16
Self-citationErickson, S. B., Pham, Q. T., Cao, X., Glicksman, J., Kelemen, R. E., Shahraeini, S. S., Bodkin, S., Kiyam, Z., & Chatterjee, A. (2023) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.3c00411 · Cited by 19
Structural characterization of a bat Adeno-associated virus capsid
Mietzsch, M., Li, Y., Kurian, J. J., Smith, J. K., Chipman, P. R., McKENNA, R. V., Yang, L., & Agbandje‐McKenna, M. (2020) · Journal of Structural Biology · doi:10.1016/j.jsb.2020.107547 · Cited by 17
Self-citationWhiteley, Z., Massaro, G., Gkogkos, G., Gavriilidis, A., Waddington, S. N., Rahim, A. A., & Craig, D. Q. M. (2023) · Nanoscale · doi:10.1039/d2nr06401d · Cited by 16
Xiang, Y. S., & Hao, G. G. (2023) · Journal of Genetic Engineering and Biotechnology · doi:10.1186/s43141-023-00518-5 · Cited by 18
“The cap gene transcribes mRNA via the p40 promoter, which is further spiced into three viral proteins (VP1, 2, 3) [11].”
BackgroundStructural and Biophysical Analysis of Adeno-Associated Virus Serotype 2 Capsid Assembly Variants
Bennett, A. D., Gargas, J., Kansol, A., Lewis, J., Hsi, J., Hull, J. A., Mietzsch, M., Tartaglia, L. J., Muzyczka, N., Bhattacharya, N., et al. (2023) · Journal of Virology · doi:10.1128/jvi.01772-22 · Cited by 19
“These loops create the surface topology of the capsid (2), which is characterized by”
BackgroundSelf-citationSingh, M., Brööks, A. G., Toofan, P., & McLuckie, K. (2023) · Gene Therapy · doi:10.1038/s41434-023-00417-x · Cited by 16
“F), through shared functional and serologic features, and two clonal isolates (AAV4 and AAV5) [21, 22].”
Structural and antigenic characterization of the avian adeno-associated virus capsid
Hsi, J., Mietzsch, M., Chipman, P. R., Afione, S. A., Zeher, A., Huang, R. K., Chiorini, J. A., & McKENNA, R. V. (2023) · Journal of Virology · doi:10.1128/jvi.00780-23 · Cited by 14
“7 kb genome is packaged into icosahedral capsids with T = 1 symmetry and diameters of ~250 Å (3).”
BackgroundThe Expression and Function of the Small Nonstructural Proteins of Adeno-Associated Viruses (AAVs)
Küz, Ç. A., McFarlin, S., & Qiu, J. (2024) · Viruses · doi:10.3390/v16081215 · Cited by 16
Complementation for an essential ancillary non-structural protein function across parvovirus genera
Mihaylov, I. S., Cotmore, S. F., & Tattersall, P. J. (2014) · Virology · doi:10.1016/j.virol.2014.07.043 · Cited by 15
Current Advances in Adeno-Associated Virus-Mediated Gene Therapy to Prevent Acquired Hearing Loss
Wu, F., Sambamurti, K., & Sha, S. (2022) · Journal of the Association for Research in Otolaryngology · doi:10.1007/s10162-022-00866-y · Cited by 15
“AAV cap is the major determinant of AAV cell tropism, as capsid sequence variants interact with unique receptors on target cells, making AAV serotypes valuable cell-targeting research tools [34].”
BackgroundLarge, E. E., & Chapman, M. S. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1116896 · Cited by 16
“Starting with the requirement of AAV2 for heparan sulfate proteoglycan in mediating attachment and infection (Summerford and Samulski, 1998), extracellular glycans of several types were implicated as receptors for different groups of AAV serotypes (Agbandje-McKenna and Kleinschmidt, 2011; Huang et al., 2014).”
BackgroundNon-canonical amino acid incorporation into AAV5 capsid enhances lung transduction in mice
Chang, H., Du, A., Jiang, J., Ren, L., Liu, N., Zhou, X., Liang, J., Gao, G., & Wang, D. (2023) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2023.101129 · Cited by 14
“29 However, we noticed that VR-III is spatially close to a b turn near the 3-fold axis (Figure 8D).”
BackgroundMethodCatalán-Tatjer, D., Tzimou, K., Nielsen, L. K., & Lavado‐García, J. (2024) · Biotechnology Advances · doi:10.1016/j.biotechadv.2024.108370 · Cited by 15
Zhang, Y., Chen, Z., Wang, X., Yan, R., Bao, H., Chu, X., Guo, L., Wang, X., Li, Y., Mu, Y., et al. (2024) · Acta Biomaterialia · doi:10.1016/j.actbio.2024.07.023 · Cited by 13
Viral vectors as a promising nanotherapeutic approach against neurodegenerative disorders
Srivastava, V., Singh, A., Jain, G. K., Ahmad, F. J., Shukla, R., & Kesharwani, P. (2021) · Process Biochemistry · doi:10.1016/j.procbio.2021.07.002 · Cited by 13
Ge, H., Shi, Z., Liu, C., Lu, J., Yao, Y., & Cheng, B. (2025) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2025.101400 · Cited by 12
Ikeda, T., Yamaguchi, Y., Oyama, H., Matsushita, A., Tsunaka, Y., Fukuhara, M., Torisu, T., & Uchiyama, S. (2024) · Viruses · doi:10.3390/v16040585 · Cited by 12
Kahlig, C., Moser, S., Mičutková, L., Grillari, J., Kraus, B., & Bort, J. A. H. (2024) · Biotechnology Journal · doi:10.1002/biot.202300672 · Cited by 12
“[46,47] Comparing different scales often show yield differences.”
BackgroundPrecise Photoremovable Perturbation of a Virus–Host Interaction
Erickson, S. B., Mukherjee, R., Kelemen, R. E., Wrobel, C. J. J., Cao, X., & Chatterjee, A. (2017) · Angewandte Chemie · doi:10.1002/ange.201700683 · Cited by 11
Gene therapy for Parkinson’s disease: a new frontier in neurodegenerative diseases
Asuku, A. O., Ogungbangbe, G. O., & Fajemidagba, G. A. (2025) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2025.1004119 · Cited by 10
Viral-mediated gene therapy in pediatric neurological disorders
Peng, J., Zou, W., Wang, X., Zhang, Z., Huo, R., & Yang, L. (2023) · World Journal of Pediatrics · doi:10.1007/s12519-022-00669-4 · Cited by 9
“Multiple factors, such as the amino acid sequence of the viral capsid, the capsid structure, host cell surface receptors, signaling molecules, proteins associated with the replication of recipient DNA, and host-derived antibodies, can all affect the transduction efficiency [67].”
Singh, M., Singh, S. P., Yadav, D., Agarwal, M., Agarwal, S., Agarwal, V., Swargiary, G., Srivastava, S., Tyagi, S., Kaur, R., et al. (2020) · Current Gene Therapy · doi:10.2174/1566523220999200817164907 · Cited by 9
Zhang, X., Chai, Z., Samulski, R. J., & Li, C. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.193 · Cited by 9
“Its capsid, which is composed of three viral proteins (VP1, VP2, and VP3), is highly variable among the 13 known AAV serotypes and numerous natural variants,(7) which leads to remarkable variability in tissue tropism and a wide application for targeted therapies.(8) The therapeutic efficacy and safety of rAAV vectors…”
BackgroundOptogenetic activation of the diaphragm
Benevides, E. S., Sunshine, M. D., Rana, S. D., & Fuller, D. D. (2022) · Scientific Reports · doi:10.1038/s41598-022-10240-w · Cited by 9
Nguyen, H. T., Shiri, F., Verber, M., McKinney, C., Choi, J., Park, S., Surtan, J., Prasannakumari, S. S., Ritola, K., & Soper, S. A. (2024) · Sensors and Actuators Reports · doi:10.1016/j.snr.2024.100242 · Cited by 8
Adeno-associated viral vectors deliver gene vaccines
Wei, L., Yu, P., Wang, H., & Liu, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.117010 · Cited by 9
Sherpa, C., & Grice, S. F. J. L. (2020) · Current HIV Research · doi:10.2174/1570162x18666200210121339 · Cited by 8
Ille, A. M., Kishel, E., Bodea, R., Ille, A. L., Lamont, H., & Amico-Ruvio, S. A. (2020) · Journal of NeuroVirology · doi:10.1007/s13365-020-00890-9 · Cited by 8
Recent advances in host-focused molecular tools for investigating host-gut microbiome interactions
Wang, S., Gong, X., Xiao, F., & Yang, Y. K. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1335036 · Cited by 9
Wang, H., Li, R., Sadekar, S., Kamath, A. V., & Shen, B. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101326 · Cited by 7
Sharma, S., Joshi, V., & Kumar, V. (2025) · Clinical and Translational Neuroscience · doi:10.3390/ctn9030032 · Cited by 7
A single amino acid variant in the variable region I of AAV capsid confers liver detargeting
Xing, R., Xu, M., Reil, D., Destefano, A., Cui, M., Liu, N., Liang, J., Xu, G., Luo, L., Xu, M., et al. (2025) · PLoS Pathogens · doi:10.1371/journal.ppat.1013533 · Cited by 7
“For example, aligning the amino acid sequences of various AAV capsids results in the identification of nine variable regions (VRs), which diverge to a higher degree than the remaining regions among different serotypes.”
PEG-mediated transduction of rAAV as a platform for spatially confined and efficient gene delivery
Zou, L., Wang, J., Fāng, Y., & Tian, H. (2022) · Biomaterials Research · doi:10.1186/s40824-022-00322-1 · Cited by 7
“Discussion The transduction efficiency of rAAV is largely depended on the cellular internalization and the following downstream events after the internalization of rAAV [42, 43].”
BackgroundRana, J., Marsic, D., Zou, C., Muñoz-Melero, M., Li, X., Kondratov, O., Li, N., de Jong, Y. P., Zolotukhin, S., & Biswas, M. (2023) · Human Gene Therapy · doi:10.1089/hum.2022.176 · Cited by 7
Protein Carrier Adeno-Associated Virus
Hoffmann, M. D., Sorensen, R. J., Extross, A., He, Y., & Schmidt, D. (2025) · ACS Nano · doi:10.1021/acsnano.5c01498 · Cited by 6
Daniel, H. D. J., Kumar, S., Kannangai, R., Farzana, J., Joel, J. N., Abraham, A., Lakshmi, K. M., Agbandje‐McKenna, M., Coleman, K. E., Srivastava, A., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27859 · Cited by 6
Self-citationA Precise Chemical Strategy To Alter the Receptor Specificity of the Adeno‐Associated Virus
Kelemen, R. E., Mukherjee, R., Cao, X., Erickson, S. B., Zheng, Y., & Chatterjee, A. (2016) · Angewandte Chemie · doi:10.1002/ange.201604067 · Cited by 7
Harnessing nucleic acid technologies for human health on earth and in space
Sarli, S. L., & Watts, J. K. (2022) · Life Sciences in Space Research · doi:10.1016/j.lssr.2022.08.006 · Cited by 6
MacLachlan, T. K., McIntyre, M., Mitrophanous, K. A., Miskin, J., Jolly, D. J., & Cavagnaro, J. A. (2013) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.008 · Cited by 6
“In the event that biodistribution studies of a particular vector class and route of administration have already been performed, sponsors may choose to cross-reference that data in subsequent INDs using that same class and ROA.”
InfluentialLai, K.-Y., Nie, S., Chen, Y.-C. A., Tiambeng, T. N., Tang, S., Huang, Y., Yan, Y., Mishra, S., Al-Rubaye, H., Hermann, A., et al. (2026) · Gene Therapy · doi:10.1038/s41434-026-00593-6 · Cited by 5
“This additional segment, known as the VP1 unique (VP1u) region, exhibits phospholipase A2 activity and is implicated in nuclear localization [4 – 6].”
Blizard, S., Park, D., O'Toole, N., Norooz, S., Torre, M. D., Son, Y., Holstein, A., Austin, S., Harman, J., Haraszti, S., et al. (2021) · Cells · doi:10.3390/cells10102654 · Cited by 5
“AAV serotypes exhibit different tissue tropism [31].”
Structures and functions of the limited natural polyclonal antibody response to parvovirus infection
Adu, O. F., Lee, H., Früh, S. P., Schoenle, M. V., Weichert, W. S., Flyak, A. I., Hafenstein, S. L., & Parrish, C. R. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2423460122 · Cited by 5
“Capsid structures have been solved at high resolutions for several parvoviruses, including those of the animal parvoviruses CPV and FPV ( 8 , 27 , 28 ), and various serotypes of AAV ( 29 , 30 ).”
Recent Advances in Canine Medicine
Fonseca‐Alves, C. E. (2022) · Veterinary medicine and science · doi:10.5772/intechopen.100825 · Cited by 6
Research Status and Applications of Adeno‐Associated Virus
Xia, K., Liu, S., Wu, Z., & Jiang, J. (2024) · ChemBioChem · doi:10.1002/cbic.202400856 · Cited by 4
Interplay between Furin and Sialoglycans in Modulating Adeno-Associated Viral Cell Entry
Smith, T. J., Fusco, R. M., Elmore, Z. C., & Asokan, A. (2023) · Journal of Virology · doi:10.1128/jvi.00093-23 · Cited by 4
“Different AAV serotype capsids are known to engage a range of cell surface attachment factors and exploit different host factors for intracellular uptake and subsequent transduction (3).”
BackgroundPushchina, E. V., Bykova, M. E., Shamshurina, E. V., & Alekseevich, V. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23094947 · Cited by 4
“However, the efficacy of rAAVs is largely determined by molecular interactions between the capsid and the target cell surface receptors [32], with subsequent downstream events after particle internalization [33].”
BackgroundTaking a Hint from Structural Biology: To Better Understand AAV Transport across the BBB
Wang, D., & Gao, G. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.01.005 · Cited by 5
“Therefore, extensive research efforts have been focused on elucidating the structural determinants of various AAV capsids that are required for specific tissue tropism and immunogenicity.(8,9) Furthermore, these insights into the structural biology of natural AAV capsids can facilitate capsid engineering to develop sa…”
BackgroundKopec, B. M., Ulapane, K. R., Moral, M. E. G., & Siahaan, T. J. (2018) · Neuromethods · doi:10.1007/978-1-4939-8946-1_2 · Cited by 4
Yin, V. C., Devine, P. W. A., Saunders, J. C., Hines, A. R., Shepherd, S., Dembek, M., Dobson, C., Snijder, J., Bond, N. J., & Heck, A. J. R. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.08.27.505551 · Cited by 4
Dou, D., Lu, J., Chen, X., & Zhang, X. (2025) · Pharmaceutical Research · doi:10.1007/s11095-025-03931-2 · Cited by 4
“The AAV capsid functions as a protective protein that encases the virus, safeguarding the nucleic acid payload from immune responses while demonstrating viral vector tropism for targeted site expression [13–15].”
Directed evolution of novel AAV capsids for enhanced delivery to mouse and human Schwann cells
Carneiro, A. D., Nisanov, A. M., Lee, H., & Schaffer, D. V. (2026) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2026.102928 · Cited by 3
“This VP1 unique region plays a role in endosomal escape and nuclear localization, 26 which may underlie the observed differences in transduction efficiency.”
An Overview of rAAV Vector Product Development for Gene Therapy
Snyder, R. O. (2015) · Stem cell biology and regenerative medicine · doi:10.1007/978-1-4939-3228-3_2 · Cited by 4
Gene Therapy: Use of Viruses as Vectors
Nance, M. E., & Duan, D. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.95711-8 · Cited by 3
Identification of a novel neutralization epitope in rhesus AAVs
Dagotto, G., Fisher, J. L., Li, D., Li, Z., Jenni, S., Li, Z., Tartaglia, L. J., Abbink, P., & Barouch, D. H. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101350 · Cited by 3
“32 Our models fi t the electron density maps well, particularly for the core of the structure (Figure 5C).”
Daniel, H. D. J., Farzana, J., Kannangai, R., Kumar, S., Lakshmi, K. M., Jashal, C. B., Dhamne, H., Lahoti, V., Kanjwani, D., Abraham, A., et al. (2025) · Human Gene Therapy · doi:10.1177/10430342251366208 · Cited by 2
HUH endonuclease-mediated DNA–protein conjugates: sequence-specific tools and cellular applications
Huang, X., Li, H., Du, J., Xie, W., Liu, Y., Lin, Y., & Xing, H. (2025) · Chemical Communications · doi:10.1039/d5cc04628a · Cited by 3
Tissue‐specific gene delivery approaches
Nasr, S. S., Cheema, Y., Stern, A., Tabah, O., Poore, S., & Duncan, G. A. (2026) · Bioengineering & Translational Medicine · doi:10.1002/btm2.70125 · Cited by 3
Gene therapy targeting the blood-brain barrier
Körbelin, J., Pereira, A. A., & Schwaninger, M. (2024) · Vitamins and hormones · doi:10.1016/bs.vh.2024.03.001 · Cited by 2
Hoyle, B., Bello, D., Hill, J., Das, S., & Kim, J. (2025) · Current Gene Therapy · doi:10.2174/0115665232369708250327081305 · Cited by 2
Grosios, K., Petry, H., & Lubelski, J. (2014) · Advances in predictive, preventive and personalised medicine · doi:10.1007/978-94-017-9214-1_9 · Cited by 2
“Numerous evidence has been collected to provide information about the tropism, or preference to transduce, of viruses used in gene therapy, including naturally occurring and modifi ed AAVs [ 11 , 21 – 23 ].”
BackgroundNash, K. R., Cárdenas‐Aguayo, M. D. C., Berg, M. J., & Marks, N. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2012.02.008 · Cited by 2
Gene Therapy for X-Linked Myotubular Myopathy
Dupont, J.-B., Lawlor, M. W., & Childers, M. K. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_32 · Cited by 2
Development of Next-Generation Muscle Gene Therapy AAV Vectors
Nance, M. E., & Duan, D. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_11 · Cited by 2
Virus-assisted directed evolution of enhanced suppressor tRNAs in mammalian cellsPreprint
Kelemen, R. E., Jewel, D., Huang, R. L., Zhu, Z., Cao, X., Pasha, M., Anthony, J. S., van Opijnen, T., & Chatterjee, A. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.21.477302 · Cited by 2
Vetter, J., Kley, M., Eichwald, C., & Fraefel, C. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.10.642135 · Cited by 1
Altering VP1 and VP2 expression in trans affects the transduction efficiency of AAV9
Efremov, M. K., Galieva, A., Brovin, A. N., Mesonzhnik, N. V., Afonin, M., Subcheva, E. N., & Karabelsky, A. V. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1753246 · Cited by 1
Gene-sized editing for the therapy of genetic diseases
Padureanu, T., Cocoş, R., Matache, I., & Bucur, O. (2026) · Functional & Integrative Genomics · doi:10.1007/s10142-026-01823-1 · Cited by 2
Pan, Y., Zhong, Y., Chen, H., Zhang, Y., Dai, Z., Chen, J., Tan, K., Chen, X., Qiu, D., Sheng, L., et al. (2026) · Molecular Therapy Advances · doi:10.1016/j.omta.2026.201725 · Cited by 1
“21 Effective viral transduction requires transgene expression, making the detection of capsids or vector genomes insufficient for confirming successful transduction.”
Gene Therapy of CNS Disorders Using Recombinant AAV Vectors
Murlidharan, G., Samulski, R. J., & Asokan, A. (2016) · Springer eBooks · doi:10.1007/978-1-4899-7654-3_2 · Cited by 1
Viral Vectors for Muscle Gene Therapy
Wang, D., Brown, A., & Gao, G. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_10 · Cited by 1
Yue, P., Zhong, Y., Chen, H., Zhang, Y., Dai, Z., Chen, J., Tan, K., Chen, X. B., Qiu, D., Sheng, L., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.19.654800 · Cited by 1
UNDERSTANDING THE SOLUTION-PHASE BIOPHYSICS AND CONFORMATIONAL DYNAMICS OF VIRUS CAPSIDS
Rayaprolu, V. (2013) · Montana State University ScholarWorks (Montana State University)
Treating Hemophilia by Gene Therapy
Porada, C. D., Ignacio, G., Atala, A., & Almeida-Porada, G. D. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800548-4.00012-7
Parvoviridae: General Features☆
Cotmore, S. F., & Tattersall, P. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.02641-6
Serotype 8 Capsid of Adeno-Associated Virus Mapping a Neutralizing Epitope onto the
Agbandje‐McKenna, M., Baker, T. S., Kleinschmidt, J. A., Naumer, M., Olson, N. H., Ng, R., Gurda, L., Raupp, C., & Popa-Wagner, R. (2012)
Self-citationBiology of AAV Vectors in the Central Nervous System
Murlidharan, G. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/cr64-be62
Adeno-associated virus-mediated gene therapy in central nervous system genetic disorders
Casy, W., Ling, Q., Shaffo, F. C., Sinnett, S. E., & Gray, S. J. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-813955-4.00010-6
Xu, J., Wang, B., & Song, L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-820007-0.00025-8 · Cited by 1
Digital Droplet PCR Method for the Quantification of AAV Transduction Efficiency in Murine Retina
Okan, I. C. T., Ahmadian, M., Tutuncu, Y., Altay, H. Y., & Ağca, C. (2021) · Journal of Visualized Experiments · doi:10.3791/63038
Kick, G. R. (2021) · MOspace Institutional Repository (University of Missouri) · doi:10.32469/10355/88127
Fehlings, M. G. (2020) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.734958350.793573257
Parvovirus Vectors: The Future of Gene Therapy
Gupta, M. (2022) · Veterinary medicine and science · doi:10.5772/intechopen.105085
Metadata
- Authors
- Agbandje-McKenna, M., & Kleinschmidt, J.
- Affiliations
- German Cancer Research Center (DE)
- Venue
- Methods in Molecular Biology
- Publisher
- Humana Press
- Published
- 2011-09-27
- Volume
- 807
- Pages
- 47-92
- ISSN
- 1064-3745 (ISSN-L)
- 1940-6029
- OpenAlex
- W124314106
- Cited by
- 215
- References
- 195
- Citations by year
- 2026: 12 · 2025: 16 · 2024: 19 · 2023: 19 · 2022: 17 · 2021: 15 · 2020: 13 · 2019: 17 · 2018: 14 · 2017: 11 · 2016: 10 · 2015: 12 · 2014: 16 · 2013: 12 · 2012: 12
- FWCI
- 32.78
- Type
- book chapter
- Language
- en
- Open access
- closed
- Licence
- Locations
- Methods in molecular biology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (R01GM082946)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Infectious Diseases › Parvovirus B19 Infection Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- adeno-associated virus, capsid structure, capsid assembly, DNA packaging, cell tropism, receptor recognition, capsid uncoating, antibody neutralization, serotypes, gene delivery vectors, host cell interactions
- MeSH terms
- Dependovirus, Antibody Formation, Capsid, Humans, Models, Molecular, Endosomes, Viral Proteins, Protein Structure, Secondary
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
